<Anchor> In



order to secure the Corona 19 vaccine, which is currently being developed, the world is moving rapidly, and Korea is also trying to secure supplies.

The health authorities secured a budget of 172 billion won for a vaccine that could fit 30 million people, which is about 60% of our population, and it was confirmed that we are currently negotiating with two foreign companies.



Reporter Nam Joo-hyun exclusively reported on what kind of company it was.



<Reporter>



Last week, the last interim clinical trial announcement that the effectiveness of Pfizer's Corona 19 vaccine was 90%, but the Korean government was not happy.



This is because Pfizer has not been able to obtain any vaccine supplies.



[Kwon Jun-wook/President of the National Institute of Health (Last 12th): Even if there is a limit to giving up the advance payment, it is sufficient, and



we

will secure and purchase as much as possible.] The Korea

Centers for Disease

Control and Prevention (KCDC)

is in the name of advance payment for vaccines for 60% of our citizens, or 30 million people. We have secured a budget of 172.3 billion won.



Cobox, an international vaccine co-purchase organization, costs 85 billion won for 10 million people and 43.6 billion won for 10 million A and B vaccines of two companies.



The two companies were confirmed to be dominant in the two companies, AstraZeneca and NovaVax, which signed a letter of intent for cooperation for domestic supply and production in July and August.



Authorities predict that the clinical results of the highly performing AstraZeneca vaccine will be released around the next week.



NovaVax vaccine with protein recombination technology has the advantage of maintaining a high neutralizing antibody titer in the vaccinated person.



In addition, health authorities are watching a vaccine from the German company CureVac, an RNA vaccine similar to Modena and Pfizer.



The CureVac vaccine is relatively slow since phase 2 clinical trials are in progress, but has the advantage that it can be stored for 3 months at 5 degrees Celsius and 24 hours at room temperature.



With pharmaceutical companies scheduled to release clinical results one after another by the end of the year, competition among countries to validate various types of vaccines and secure sufficient quantities is expected to intensify.



(Video coverage: Seol Min-hwan, video editing: Lee Seung-yeol)



▶'

Underwater    

contact' Astra vaccine, when can we inoculate?


▶ "Modern vaccine prevention rate 94.5%"...

US "approves as soon as possible"